Abstract The World Health Organization classification of lymphoid neoplasms updated in
2008 represents a worldwide consensus on the diagnosis of these tumors and is based on …

New systems have emerged for diagnosis, staging and response assessment in multiple
myeloma (MM). The diagnostic and response criteria recommended are primarily derived …

Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …

PURPOSE We report the long-term findings and final analysis of a pivotal multicenter trial of
ibrutinib monotherapy in previously treated patients with Waldenström macroglobulinemia …

Background MYD88 L265P and CXCR4WHIM mutations are highly prevalent in
Waldenström's macroglobulinemia. MYD88L265P triggers tumor-cell growth through …

Background Single-agent ibrutinib has shown substantial activity in patients with relapsed
Waldenström's macroglobulinemia, a rare form of B-cell lymphoma. We evaluated the effect …

Background Waldenström's macroglobulinemia is an incurable, IgM-secreting
lymphoplasmacytic lymphoma (LPL). The underlying mutation in this disorder has not been …

The genetic basis for Waldenström macroglobulinemia (WM) remains to be clarified.
Although 6q losses are commonly present, recurring gene losses in this region remain to be …

PURPOSE BCL2 is overexpressed and confers prosurvival signaling in malignant
lymphoplasmacytic cells in Waldenström macroglobulinemia (WM). Venetoclax is a potent …

Herein, we present the final report of a single-center, prospective phase II study evaluating
ibrutinib 420 mg once daily in 30 treatment-naive patients with Waldenstrom …